Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management

@article{Moore2017PegfilgrastimInducedBP,
  title={Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management},
  author={Donald C. Moore and Annie Pellegrino},
  journal={Annals of Pharmacotherapy},
  year={2017},
  volume={51},
  pages={797 - 803}
}
Objective: To review the incidence, risk factors, and management of pegfilgrastim-induced bone pain (PIBP). Data Sources: PubMed was searched from 1980 to March 31, 2017, using the terms pegfilgrastim and bone pain. Study Selection and Data Extraction: English-language, human studies and reviews assessing the incidence, risk factors, and management of PIBP were incorporated. Data Synthesis: A total of 3 randomized, prospective studies and 2 retrospective studies evaluated pharmacological… 

Tables from this paper

Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis

Administration of pegfilgrastim co-administration is an independent risk factor for G2 and all-grade T-APS, and age younger than 55 years is a risk factor of all- grade T-aps under prophylactic DEX administration.

Efficacy of “Naproxen and Loratadine” Versus “Acetaminophen and Loratadine” on Relief of Pegylated Granulocyte Colony Stimulating Factor (Peg-G-CSF)-Induced Bone Pain During Chemotherapy; A Randomized Controlled Trial

By controlling the effects of age, sex, and baseline pain, Naproxen in the second and subsequent courses of treatment was significantly better than Acetaminophen in reducing pain.

Oral loratadine in the management of G-CSF-induced bone pain: a pilot study.

Oral loratadine was found to be associated with pain reduction in patients with cancer receiving G-CSFs, and it was found that bone pain induced by granulocyte-colony stimulating factors can be alleviated or eliminated by oral antihistamine lor atadine.

Neurophysiological Mechanisms Related to Pain Management in Bone Tumors

Cancer-induced bone pain could include neuropathic and inflammatory pain, but with different modifications to the periphery tissue, nerves and neurochemical changes in different neurological levels, and opportunity areas in pharmacological and non-pharmacological pain management are explored.

Evaluating the safety and effectiveness of PegaGen® (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study

The results from this post-marketing surveillance study support the safety and effectiveness of PegaGen® used for the prevention of chemotherapy-induced FN in patients with various types of cancer and treatment regimens.

Can loratadine help in treating granulocyte-colony stimulating factor-induced bone pain?

Although more research is needed, loratadine's tolerability, ease of administration, and potential benefit mean that it should be considered for management of pegfilgrastim-associated bone pain.

Comparative Study of Adverse Drug Reactions Associated with Filgrastim and Pegfilgrastim Using the EudraVigilance Database

It is demonstrated that the occurrence of bone pain was similar with FIL and PEG-F, and the incidence of neutropenia and febrile neutropania was higher in FIL compared to P EG-F.

Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim, and bone pain reduction, thrombocytopenia reduction, and quality of life maintenance will be secondary end points.

Title Oral loratadine in the management of G-CSF induced bone pain: a pilot study

Oral loratadine in the management of G-CSFinduced bone pain: a pilot study.

Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study

The combination therapy with Peg G and mFFX markedly prolonged the progression-free survival compared with the non-Peg G group, and its effects were associated with a reduced incidence of neutropenic events as well as lower rates of dosage reduction, delayed chemotherapy due to neutropic events and altered blood cell counts after chemotherapy.

References

SHOWING 1-10 OF 29 REFERENCES

Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients

Pegfilgrastim is commonly used for primary prophylaxis during the first cycle of chemotherapy, and loratadine was the most commonly employed medication to mitigate this adverse effect.

Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim

Administration of prophylactic loratadine does not decrease the incidence of severe bone pain or improve quality of life in a high-risk patient population.

Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base.

It is demonstrated that naproxen at a dose of 500 mg twice per day is effective in reducing the incidence and severity of pegfilgrastim-induced bone pain.

Severe pegfilgrastim-induced bone pain completely alleviated with loratadine: A case report

  • C. RomeoQuan-wang LiL. Copeland
  • Medicine
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2015
The first case report in which loratadine prophylaxis completely alleviated NSAID-resistant severe pain secondary to pegfilgrastim is presented, showing that lor atadine may be a promising option for severe, resistant pegfilGrastim-induced bone pain.

Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.

Among patients with bone pain, a trend towards earlier onset with pegfilgrastim was observed but was not associated with increased bone pain severity or duration, and no statistically significant differences in incidence, severity, or duration were observed between patients receiving either once-per-cycle pegfil Grastim or daily filgrastIM in either study.

Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim

Potential risk factors for bone pain in patients receiving myelosuppressive chemotherapy and primary prophylactic pegfilgrastim identified in this study are younger age and history of bone pain.

Empiric dose reduction of pegfilgrastim in breast cancer patients receiving cytotoxic chemotherapy

Empiric dose reduction from 6mg to 4mg administered on the day after chemotherapy was used to ameliorate pain while maintaining count recovery in patients who had empiric dose reductions because of bone pain with concomitant normal or high leukocyte counts during recovery.

Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade

The use of a double histamine blockade is an inexpensive, safe, and effective way to alleviate bone pain symptoms secondary to G-CSF agents.